NAFLD is a clinical syndrome characterized by predominant macrovesicular steatosis of the
liver. The clinical and histological phenotypes of NAFLD extend from a nonalcoholic fatty …

In the last years new evidence has accumulated on nonalcoholic fatty liver disease (NAFLD)
challenging the paradigms that had been holding the scene over the previous 30 years …

Non-alcoholic fatty liver disease (NAFLD) is the hepatic manifestation of the global obesity
and metabolic disease epidemic and is rapidly becoming the leading cause of liver cirrhosis …

Background: Obesity is often associated with nonalcoholic fatty liver disease (NAFLD),
which refers to a large spectrum of hepatic lesions including fatty liver, nonalcoholic …

Aim The diagnosis of non‐alcoholic steatohepatitis (NASH) is based on the individual
histological features: steatosis, lobular inflammation and ballooning. Non‐alcoholic fatty liver …

Obesity is commonly associated with nonalcoholic fatty liver (NAFL), a benign condition
characterized by hepatic lipid accumulation. However, NAFL can progress in some patients …

Cannabis sativa, a subspecies of the Cannabis plant, contains aromatic hydrocarbon
compounds called cannabinoids.∆ 9-Tetrahydrocannabinol is the most abundant …

Over the past decades, many drugs have been identified, that can potentially induce
steatohepatitis in the predisposed individual. Classically this has been incriminated to …

Lipotoxicity associated with insulin resistance is central to nonalcoholic steatohepatitis
(NASH) pathogenesis. To date, only weight loss fully reverses NASH pathology, but mixed …

Nonalcoholic fatty liver disease (NAFLD) is recognized as the most common cause of
chronic liver disease in the United States. Nonalcoholic steatohepatitis (NASH) occurs in a …